ANPCY News and Press, Angle Plc Surrey ADR From 06/27/23

GUILDFORD, SURREY / ACCESSWIRE / June 27, 2023 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN Issuer Name UK or Non-UK Issuer 2. Reason for Notification 3. Details of person subject to the notification obligation Name City of registered off...

Brett Swansiger joins as Chief Commercial Officer Karen Miller PhD joins as Chief Scientific Officer GUILDFORD, SURREY / ACCESSWIRE / June 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the appointments of Br...

Pharma Services Contract Win Parsortix DNA Damage Response Assays developed by ANGLE to be used for exploratory objectives in a Phase 1 clinical trial Trial expected to complete by year end 2024 GUILDFORD, SURREY / ACCESSWIRE / May 25, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a worl...

GUILDFORD, SURREY / ACCESSWIRE / May 22, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September. Garth will hand over the Cha...

GUILDFORD, SURREY / ACCESSWIRE / April 21, 2023 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce it will be presenting via the Investor Meet Company platform at 11:00 am (BST) on Friday 28 April 2023. The presentation by Andrew Newland and Ian Gri...

Preliminary Results for the year ended 31 December 2022 FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPS Parsortix system substantially out-performs standard of care for ovarian cancer diagnosis Prostate cancer partnership signed with Solaris Health Pipeline of op...

2023-04-19 06:51:28 ET ANGLE ( OTCQX:ANPCY ) signs an agreement with BioView to develop a liquid biopsy circulating tumor cell (or CTC) HER2 assay for breast cancer. It will be utilising ANGLE's FDA cleared Parsortix PC1 Clinical System to harvest CTCs and BioView's autom...

HER2 ASSAY DEVELOPMENT PARTNERSHIP WITH BIOVIEW Agreement with BioView to develop a CTC-based HER2 assay First phase expected to generate c. £1.2 million revenue GUILDFORD, UK / ACCESSWIRE / April 19, 2023 / ANGLE plc (AIM:AGL), (OTCQX:ANPCY), a world-leading liquid biopsy com...

PARSORTIX POSTER PRESENTED AT AACR ANNUAL MEETING 2023 Study demonstrates the feasibility of combining IF and HER2 FISH analysis with CTCs harvested using the Parsortix system Capability to measure HER2 protein overexpression on CTCs using ANGLE's Portrait Flex assay opens up substantia...

2023-04-13 05:00:23 ET Liquid biopsy company, ANGLE ( OTCQX:ANPCY ) has signed a contract with a new customer, Crescendo Biologics. Crescendo is a UK-based, clinical stage immuno-oncology company with an extensive proprietary pipeline of novel, targeted T cell enhanc...